A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
|Webcasts|September 29, 2021
Increasing Upstream Bioprocessing Efficiency through Process Analytical Technology
Author(s)Eppendorf
Wednesday, September 29, 2021 at 10am EDT| 7am PDT| 3pm BST| 4pm CEST Learn about strategies for inline process analytics aimed at automated feed control in an upstream bioprocess. Using the example of a Raman analyzer, a glucose analyzer, and an exhaust analyzer experts demonstrate how to achieve seamless sensor integration with the bioprocess control software.
In biologics production, the upstream bioprocess contributes significantly to product quality and manufacturing efficiency. A comprehensive understanding on which process parameters are critical and how they influence process outcome allows the development of tailored control strategies and consistent process performance.
Compared to offline measurements of a sample that has been taken from a bioreactor, inline analysis of process parameters reduces the manual workload and facilitates the implementation of automated feedback control loops. While inline analytics of some process parameters, such as temperature, dissolved oxygen, and pH are well established, real-time measurement of others—such as metabolite concentrations or cell viability—is not yet routine.
This webcast presents strategies for inline process analytics aimed at automated feed control in an upstream bioprocess. Using the example of a Raman analyzer, a glucose analyzer, and an exhaust analyzer experts will demonstrate, how to achieve seamless sensor integration with the bioprocess control software while keeping the glucose concentration stable during the bioprocess run and minimizing human intervention.
Key Learning Objectives:
- Get to know how inline process analytics can improve bioprocess efficiency
- Learn which bioreactor software features are needed to integrate analyzers and to implement automated feedback control loops
- Benefit from hands-on experience in integrating analyzers to automate culture feeding
Register Free:
Related to this article
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
Trending on BioPharm International
1
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
2
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
3
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
4
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
5